A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate
A serum test called T50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients in...
Gespeichert in:
| Veröffentlicht in: | Clinical transplantation 2017-12, Vol.31 (12), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 12 |
| container_start_page | |
| container_title | Clinical transplantation |
| container_volume | 31 |
| creator | Smerud, Knut T. Åsberg, Anders Kile, Håkon Pasch, Andreas Dahle, Dag O. Bollerslev, Jens Godang, Kristin Hartmann, Anders |
| description | A serum test called T50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T50 at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T50 was a significant covariate (P |
| doi_str_mv | 10.1111/ctr.13131 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_crist</sourceid><recordid>TN_cdi_cristin_nora_10852_61715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1946430752</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3841-5f13be808a893e2b89a266f74115b6a4edba7bad5bda2e092d81a9b81ca129853</originalsourceid><addsrcrecordid>eNp1kU1vVCEUhonR2LG68A8oy3YxLXC_wF0z8StpYtKMa3IunJugXBiBq7n-Lf-gTKd1Jyw4gSfPAV5CXnN2xeu4NiVd8abOJ2TDG6W2jHHxlGyYYqLWfXNGXuT8re72vO-ekzMh1SD6odmQPzc0wcFZCsHSvOQCLqClbj6k-BNnDIXGiRrwxk3OQHEx0Hp0wJBdWWk2MSG9yJiWme47dklhKpiqyRjMeVo8_e5swJWWBCEfPIRyL3lH7xAC-DW7fOwA9RrBxtn9rt1NDCVF72tZkgN_BNxYz1MMUPAleTaBz_jqYT0nXz-83-8-bW-_fPy8u7ndmka2fNtNvBlRMglSNShGqUD0_TS0nHdjDy3aEYYRbDdaEMiUsJKDGiU3wIWSXXNO3p68JrlcXNAhJtCcyU7ong_8SFyciPolPxbMRc8uG_T1mRiXrLlq-7ZhQycqevkoizknnPQhuRnSWoX6mKKuKer7FCv75kG7jDPaf-RjbBW4PgG_nMf1_ya929-dlH8BMYepmQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1946430752</pqid></control><display><type>article</type><title>A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Smerud, Knut T. ; Åsberg, Anders ; Kile, Håkon ; Pasch, Andreas ; Dahle, Dag O. ; Bollerslev, Jens ; Godang, Kristin ; Hartmann, Anders</creator><creatorcontrib>Smerud, Knut T. ; Åsberg, Anders ; Kile, Håkon ; Pasch, Andreas ; Dahle, Dag O. ; Bollerslev, Jens ; Godang, Kristin ; Hartmann, Anders</creatorcontrib><description>A serum test called T50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T50 at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T50 was a significant covariate (P < .0001) for T50 scores at 10 weeks and 1 year. In the total cohort, there was a highly significant (P < .0001) increase in T50 of 26.6% after 10 weeks and T50 remained stable after 1 year. T50 change was inversely correlated to phosphate of −0.515 (P < .0001) and to change in serum albumin (P < .03). We found that T50 increased from baseline to 10 weeks after transplantation with no further change after 1 year. Ibandronate had no effect on T50.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/ctr.13131</identifier><identifier>PMID: 28972673</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing</publisher><subject>1‐year longitudinal randomized placebo‐controlled clinical trial ; Bone Density Conservation Agents - therapeutic use ; calcification propensity score T50 ; Calcinosis - drug therapy ; Calcinosis - epidemiology ; Diphosphonates - therapeutic use ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Survival - drug effects ; Humans ; ibandronate ; Kidney Failure, Chronic - surgery ; Kidney Function Tests ; kidney transplantation ; Kidney Transplantation - methods ; Male ; Middle Aged ; Norway - epidemiology ; Prognosis ; Propensity Score ; Prospective Studies ; Risk Factors</subject><ispartof>Clinical transplantation, 2017-12, Vol.31 (12), p.n/a</ispartof><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3841-5f13be808a893e2b89a266f74115b6a4edba7bad5bda2e092d81a9b81ca129853</citedby><cites>FETCH-LOGICAL-c3841-5f13be808a893e2b89a266f74115b6a4edba7bad5bda2e092d81a9b81ca129853</cites><orcidid>0000-0001-6647-686X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fctr.13131$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fctr.13131$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,26544,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28972673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smerud, Knut T.</creatorcontrib><creatorcontrib>Åsberg, Anders</creatorcontrib><creatorcontrib>Kile, Håkon</creatorcontrib><creatorcontrib>Pasch, Andreas</creatorcontrib><creatorcontrib>Dahle, Dag O.</creatorcontrib><creatorcontrib>Bollerslev, Jens</creatorcontrib><creatorcontrib>Godang, Kristin</creatorcontrib><creatorcontrib>Hartmann, Anders</creatorcontrib><title>A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>A serum test called T50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T50 at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T50 was a significant covariate (P < .0001) for T50 scores at 10 weeks and 1 year. In the total cohort, there was a highly significant (P < .0001) increase in T50 of 26.6% after 10 weeks and T50 remained stable after 1 year. T50 change was inversely correlated to phosphate of −0.515 (P < .0001) and to change in serum albumin (P < .03). We found that T50 increased from baseline to 10 weeks after transplantation with no further change after 1 year. Ibandronate had no effect on T50.</description><subject>1‐year longitudinal randomized placebo‐controlled clinical trial</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>calcification propensity score T50</subject><subject>Calcinosis - drug therapy</subject><subject>Calcinosis - epidemiology</subject><subject>Diphosphonates - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerular Filtration Rate</subject><subject>Graft Survival - drug effects</subject><subject>Humans</subject><subject>ibandronate</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Kidney Function Tests</subject><subject>kidney transplantation</subject><subject>Kidney Transplantation - methods</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Norway - epidemiology</subject><subject>Prognosis</subject><subject>Propensity Score</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>3HK</sourceid><recordid>eNp1kU1vVCEUhonR2LG68A8oy3YxLXC_wF0z8StpYtKMa3IunJugXBiBq7n-Lf-gTKd1Jyw4gSfPAV5CXnN2xeu4NiVd8abOJ2TDG6W2jHHxlGyYYqLWfXNGXuT8re72vO-ekzMh1SD6odmQPzc0wcFZCsHSvOQCLqClbj6k-BNnDIXGiRrwxk3OQHEx0Hp0wJBdWWk2MSG9yJiWme47dklhKpiqyRjMeVo8_e5swJWWBCEfPIRyL3lH7xAC-DW7fOwA9RrBxtn9rt1NDCVF72tZkgN_BNxYz1MMUPAleTaBz_jqYT0nXz-83-8-bW-_fPy8u7ndmka2fNtNvBlRMglSNShGqUD0_TS0nHdjDy3aEYYRbDdaEMiUsJKDGiU3wIWSXXNO3p68JrlcXNAhJtCcyU7ong_8SFyciPolPxbMRc8uG_T1mRiXrLlq-7ZhQycqevkoizknnPQhuRnSWoX6mKKuKer7FCv75kG7jDPaf-RjbBW4PgG_nMf1_ya929-dlH8BMYepmQ</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Smerud, Knut T.</creator><creator>Åsberg, Anders</creator><creator>Kile, Håkon</creator><creator>Pasch, Andreas</creator><creator>Dahle, Dag O.</creator><creator>Bollerslev, Jens</creator><creator>Godang, Kristin</creator><creator>Hartmann, Anders</creator><general>Blackwell Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>3HK</scope><orcidid>https://orcid.org/0000-0001-6647-686X</orcidid></search><sort><creationdate>201712</creationdate><title>A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate</title><author>Smerud, Knut T. ; Åsberg, Anders ; Kile, Håkon ; Pasch, Andreas ; Dahle, Dag O. ; Bollerslev, Jens ; Godang, Kristin ; Hartmann, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3841-5f13be808a893e2b89a266f74115b6a4edba7bad5bda2e092d81a9b81ca129853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>1‐year longitudinal randomized placebo‐controlled clinical trial</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>calcification propensity score T50</topic><topic>Calcinosis - drug therapy</topic><topic>Calcinosis - epidemiology</topic><topic>Diphosphonates - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerular Filtration Rate</topic><topic>Graft Survival - drug effects</topic><topic>Humans</topic><topic>ibandronate</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Kidney Function Tests</topic><topic>kidney transplantation</topic><topic>Kidney Transplantation - methods</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Norway - epidemiology</topic><topic>Prognosis</topic><topic>Propensity Score</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smerud, Knut T.</creatorcontrib><creatorcontrib>Åsberg, Anders</creatorcontrib><creatorcontrib>Kile, Håkon</creatorcontrib><creatorcontrib>Pasch, Andreas</creatorcontrib><creatorcontrib>Dahle, Dag O.</creatorcontrib><creatorcontrib>Bollerslev, Jens</creatorcontrib><creatorcontrib>Godang, Kristin</creatorcontrib><creatorcontrib>Hartmann, Anders</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smerud, Knut T.</au><au>Åsberg, Anders</au><au>Kile, Håkon</au><au>Pasch, Andreas</au><au>Dahle, Dag O.</au><au>Bollerslev, Jens</au><au>Godang, Kristin</au><au>Hartmann, Anders</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2017-12</date><risdate>2017</risdate><volume>31</volume><issue>12</issue><epage>n/a</epage><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>A serum test called T50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T50 at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T50 was a significant covariate (P < .0001) for T50 scores at 10 weeks and 1 year. In the total cohort, there was a highly significant (P < .0001) increase in T50 of 26.6% after 10 weeks and T50 remained stable after 1 year. T50 change was inversely correlated to phosphate of −0.515 (P < .0001) and to change in serum albumin (P < .03). We found that T50 increased from baseline to 10 weeks after transplantation with no further change after 1 year. Ibandronate had no effect on T50.</abstract><cop>Denmark</cop><pub>Blackwell Publishing</pub><pmid>28972673</pmid><doi>10.1111/ctr.13131</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6647-686X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-0063 |
| ispartof | Clinical transplantation, 2017-12, Vol.31 (12), p.n/a |
| issn | 0902-0063 1399-0012 |
| language | eng |
| recordid | cdi_cristin_nora_10852_61715 |
| source | MEDLINE; NORA - Norwegian Open Research Archives; Wiley Online Library Journals Frontfile Complete |
| subjects | 1‐year longitudinal randomized placebo‐controlled clinical trial Bone Density Conservation Agents - therapeutic use calcification propensity score T50 Calcinosis - drug therapy Calcinosis - epidemiology Diphosphonates - therapeutic use Female Follow-Up Studies Glomerular Filtration Rate Graft Survival - drug effects Humans ibandronate Kidney Failure, Chronic - surgery Kidney Function Tests kidney transplantation Kidney Transplantation - methods Male Middle Aged Norway - epidemiology Prognosis Propensity Score Prospective Studies Risk Factors |
| title | A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A17%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_crist&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20rapid%20and%20sustained%20improvement%20of%20calcification%20propensity%20score%20(serum%20T50)%20after%20successful%20kidney%20transplantation:%20Reanalysis%20of%20a%20randomized%20controlled%20trial%20of%20ibandronate&rft.jtitle=Clinical%20transplantation&rft.au=Smerud,%20Knut%20T.&rft.date=2017-12&rft.volume=31&rft.issue=12&rft.epage=n/a&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/ctr.13131&rft_dat=%3Cproquest_crist%3E1946430752%3C/proquest_crist%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1946430752&rft_id=info:pmid/28972673&rfr_iscdi=true |